Recent legislation in a number of countries has boosted the numbers—for instance, now NIH-funded studies in the United States have to justify why they’re not including women in a clinical trial if they fail to—but there remain enough loopholes in the system to drive all the elephants in a three-ring circus through (Geller et al., 2018; Rechlin et al., 2021).
